{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:21:37Z","timestamp":1784784097091,"version":"3.55.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In case 1, a 14-month-old male child with sickle cell disease (SCD) was referred for evaluation for an allogeneic hematopoietic stem cell transplant (HCT). The patient had a history of dactylitis 3 times in his first year of life and febrile episodes twice at the consult. His 4-year-old sister was found to be human leukocyte antigen (HLA) identical. The patient was started on hydroxyurea (HU) at 2.5 years of age. His parents again sought consultation when he was 5 years old because of concerns about his medical condition. At the time, the patient had experienced 2 vaso-occlusive pain episodes (VOEs) requiring hospitalization during the previous 2 years. He had also experienced intermittent pain crises requiring rest at home for 2 to 3 days. The child has not attended school in person due to the COVID-19 pandemic. The family is considering HCT but is ambivalent about it because of potential toxicity. In case 2, an 8-year-old female child is 3 years out from HCT for SCD from her HLA-identical sibling. Before HCT, despite receiving HU, she had experienced &amp;gt;5 VOEs requiring hospitalization and 2 episodes of acute chest syndromes in the previous 3 years. She had also been missing almost 50 days of school days each year. After HCT, she is now attending school regularly and participating in all normal age-appropriate activities. The parents believe that HCT has been transformative in their child's life.<\/jats:p>","DOI":"10.1182\/hematology.2021000322","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:09:34Z","timestamp":1639138174000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?"],"prefix":"10.1182","volume":"2021","author":[{"given":"Niketa","family":"Shah","sequence":"first","affiliation":[{"name":"Section of Pediatric Hematology\/Oncology\/BMT, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmanan","family":"Krishnamurti","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"25","key":"2021121012064249100_hem2021000322C1","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2019000821","article-title":"How I treat sickle cell disease with hematopoietic cell transplantation","volume":"134","author":"Stenger","year":"2019","journal-title":"Blood"},{"issue":"4, suppl","key":"2021121012064249100_hem2021000322C2","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"1, suppl 1","key":"2021121012064249100_hem2021000322C3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amepre.2015.11.002","article-title":"Sickle cell disease: a continued call to action","volume":"51","author":"Hassell","year":"2016","journal-title":"Am J Prev Med"},{"key":"2021121012064249100_hem2021000322C4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fphys.2020.00435","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas Cisneros","year":"2020","journal-title":"Front Physiol"},{"issue":"10019","key":"2021121012064249100_hem2021000322C5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia\u2014TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"2021121012064249100_hem2021000322C6","doi-asserted-by":"crossref","first-page":"e27778","DOI":"10.1002\/pbc.27778","article-title":"Hydroxyurea for children with sickle cell anemia: prescribe it early and often","volume":"66","author":"Ware","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2021121012064249100_hem2021000322C7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.25799","article-title":"Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: the PUSH study","volume":"95","author":"Nouraie","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"2021121012064249100_hem2021000322C8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","article-title":"Voxelotor: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"2021121012064249100_hem2021000322C9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1177\/0148607117727271","article-title":"Food and Drug Administration approval of glutamine for sickle cell disease: success and precautions in glutamine research","volume":"41","author":"Wilmore","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"9","key":"2021121012064249100_hem2021000322C10","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease","volume":"104","author":"Carden","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"2021121012064249100_hem2021000322C11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"6","key":"2021121012064249100_hem2021000322C12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2021121012064249100_hem2021000322C13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ppul.20883","article-title":"Growth of lung function in children with sickle cell anemia","volume":"43","author":"Field","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"2021121012064249100_hem2021000322C14","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1681\/ASN.2002010084","article-title":"Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure","volume":"17","author":"Guasch","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2021121012064249100_hem2021000322C15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"2021121012064249100_hem2021000322C16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1001\/jama.2010.562","article-title":"Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia","volume":"303","author":"Vichinsky","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"2021121012064249100_hem2021000322C17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","article-title":"Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study","volume":"17","author":"Shah","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2021121012064249100_hem2021000322C18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121012064249100_hem2021000322C19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease","volume":"16","author":"Walters","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2021121012064249100_hem2021000322C20","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121012064249100_hem2021000322C21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2021121012064249100_hem2021000322C22","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2021121012064249100_hem2021000322C23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2021121012064249100_hem2021000322C24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2021121012064249100_hem2021000322C25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jama.2018.20059","article-title":"Association of matched sibling donor hematopoietic stem cell transplantation with transcranial doppler velocities in children with sickle cell anemia","volume":"321","author":"Bernaudin","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"2021121012064249100_hem2021000322C26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2021121012064249100_hem2021000322C27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"2021121012064249100_hem2021000322C28","doi-asserted-by":"crossref","first-page":"e28749","DOI":"10.1002\/pbc.28749","article-title":"Primary caregiver decision-making in hematopoietic cell transplantation and gene therapy for sickle cell disease","volume":"68","author":"Sinha","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2021121012064249100_hem2021000322C29","first-page":"310","article-title":"Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions","volume":"3","author":"Walters","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2021121012064249100_hem2021000322C30","first-page":"183","article-title":"Understanding pain and improving management of sickle cell disease: the PiSCES study","volume":"97","author":"Smith","year":"2005","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"2021121012064249100_hem2021000322C31","first-page":"27","article-title":"Availability of related donors for bone marrow transplantation in sickle cell anemia","volume":"16","author":"Mentzer","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"4","key":"2021121012064249100_hem2021000322C32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121012064249100_hem2021000322C33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2021121012064249100_hem2021000322C34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/bloodadvances.2020002948","article-title":"A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy","volume":"5","author":"Badawy","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2021121012064249100_hem2021000322C35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0193945918768277","article-title":"Health-related quality of life and personal life goals of adults with sickle cell disease after hematopoietic stem cell transplantation","volume":"41","author":"Gallo","year":"2019","journal-title":"West J Nurs Res"},{"issue":"3","key":"2021121012064249100_hem2021000322C36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2021121012064249100_hem2021000322C37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2021121012064249100_hem2021000322C38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.14167","article-title":"Haematopoietic stem cell transplantation for sickle cell disease\u2014current practice and new approaches","volume":"174","author":"Arnold","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2021121012064249100_hem2021000322C39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2021121012064249100_hem2021000322C40","doi-asserted-by":"crossref","first-page":"696.e1","DOI":"10.1016\/j.jtct.2021.04.001","article-title":"Safety of surgical fertility preservation procedures in children prior to hematopoietic stem cell transplant","volume":"27","author":"Brodigan","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2021121012064249100_hem2021000322C41","doi-asserted-by":"crossref","first-page":"150861","DOI":"10.1016\/j.sempedsurg.2019.150861","article-title":"A fertility preservation toolkit for pediatric surgeons caring for children with cancer","volume":"28","author":"Lautz","year":"2019","journal-title":"Semin Pediatr Surg"},{"issue":"6","key":"2021121012064249100_hem2021000322C42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.2020006270","article-title":"Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease","volume":"137","author":"Joseph","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2021121012064249100_hem2021000322C43","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bjh.16976","article-title":"Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide","volume":"191","author":"Pecker","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2021121012064249100_hem2021000322C44","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/bloodadvances.2019000839","article-title":"Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases","volume":"4","author":"Kahn","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2021121012064249100_hem2021000322C45","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2021121012064249100_hem2021000322C46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2021121012064249100_hem2021000322C47","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","article-title":"Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic stem cell transplantation","volume":"23","author":"Shenoy","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2021121012064249100_hem2021000322C48","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2021121012064249100_hem2021000322C49","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2011-01-332510","article-title":"Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now","volume":"118","author":"Hsieh","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2021121012064249100_hem2021000322C50","doi-asserted-by":"crossref","first-page":"e0229710","DOI":"10.1371\/journal.pone.0229710","article-title":"Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease","volume":"15","author":"Saraf","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"2021121012064249100_hem2021000322C51","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3324\/haematol.2017.169581","article-title":"Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases","volume":"102","author":"Arnold","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2021121012064249100_hem2021000322C52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MOH.0000000000000581","article-title":"Current and future gene therapies for hemoglobinopathies","volume":"27","author":"Brendel","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2021121012064249100_hem2021000322C53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3949\/ccjm.87a.19124","article-title":"Gene therapy in sickle cell disease: possible utility and impact","volume":"87","author":"Curtis","year":"2020","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"2021121012064249100_hem2021000322C54","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcyt.2018.04.003","article-title":"Gene therapy for sickle cell disease: an update","volume":"20","author":"Demirci","year":"2018","journal-title":"Cytotherapy"},{"issue":"3","key":"2021121012064249100_hem2021000322C55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"R1","key":"2021121012064249100_hem2021000322C56","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1093\/hmg\/ddz172","article-title":"Gene therapy of hemoglobinopathies: progress and future challenges","volume":"28","author":"Ikawa","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2021121012064249100_hem2021000322C57","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021011488","article-title":"Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither","volume":"138","author":"Jones","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2021121012064249100_hem2021000322C58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bjh.16437","article-title":"Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?","volume":"189","author":"Leonard","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"2021121012064249100_hem2021000322C59","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.bbmt.2017.11.018","article-title":"Experiences and decision making in hematopoietic stem cell transplant in sickle cell disease: patients' and caregivers' perspectives","volume":"24","author":"Khemani","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2021121012064249100_hem2021000322C60","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.pec.2020.10.011","article-title":"Navigating decisional conflict as a family when facing the decision of stem cell transplant for a child or adolescent with sickle cell disease","volume":"104","author":"Schulz","year":"2021","journal-title":"Patient Educ Couns"},{"issue":"6","key":"2021121012064249100_hem2021000322C61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1703208","article-title":"Allogeneic stem cell transplantation for sickle cell disease: a study of patients' decisions","volume":"28","author":"van Besien","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2021121012064249100_hem2021000322C62","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199111073251905","article-title":"Bone marrow transplantation for sickle cell disease: a study of parents' decisions","volume":"325","author":"Kodish","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121012064249100_hem2021000322C63","doi-asserted-by":"crossref","first-page":"e206742","DOI":"10.1001\/jamanetworkopen.2020.6742","article-title":"Assessment of patient and caregiver attitudes and approaches to decision-making regarding bone marrow transplant for sickle cell disease: a qualitative study","volume":"3","author":"Bakshi","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/190\/1851641\/190shah.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/190\/1851641\/190shah.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:10:23Z","timestamp":1639138223000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/190\/482945\/Evidence-Based-Minireview-In-young-children-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000322","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}